M2M Pharmaceuticals Ltd

We are ready to Welcome you. Please come along to celebrate and Inspire others.

This is for all Guests arriving between 2 and 3pm on Monday the 4th Nov 2024 at M2M Pharma: We will be delighted to show you around and give a brief outline of these platforms so that when you go back, reflect what you have seen here and add to your projects. At the end, we all are here to facilitate product development, reduce risks, save time and money. Why not wonder about ACT, SSD, CiAD and DiP? #m2mpharma

Preparing for our King’s Award Presentation Ceremony on Monday, 4th Nov 2024.

RDD Asia 2024: Shall we have a healthy discussion on following: a) How to make amorphous form of FP and why the method should be reproducible and robust? b) Why Quench cooling mustn’t be even attempted for FP, but this is the only method works for SX. c) There is no Standard amorphous material - why so? 4) What should be there in specifications? 5) What data regulatory authorities are expecting from you? Please register and attend our Workshop. #m2mpharma

Join our workshop at RDD Asia 2024: 19-21 Nov, 2024: This workshop will cover how to handle inhaled APIs, formulations from solid-state perspectives. We will demonstrate how to use a proprietary platform (ACT) to understand and control amorphous material. We will also talk about other platforms like SSD, CiAD and DiP. At the end, we would like to share how DATA facilitate Product Development, Reduce Risks, Save Time & Money. #m2mpharma #act #ssd #ciad #dip #rddasia2024 So, please register.

Simply gearing up for our “the King’s Award Presentation Ceremony on 4th Nov, Monday. As we stand, we have 87 confirmed industry peers and UK’s thought provoking academicians. We look forward to welcoming you.

Are you frustrated by your SEM image provider from quality of images, cost and timelines perspectives? If so, M2M Pharma is the answer. At M2M Pharma, we provide industry's best images, at a reasonable cost and often within 48 hours. This is what our client states about our images: "These are one of the best images I have seen so far, good resolution and very clear. My colleagues have the same feedback." #m2mpharma #act #ssd #sem #imaging

RDD Asia in Kochi 19-21 Nov calling: We will be running a workshop and exhibiting there. Would you please get your questions ready for APIs such as FP, SX, TBM, Bud, Beclo, FF, UME, VLT, Inda, Glyco etc… Specially their amorphous form, stability, how to handle them! We look forward to exchange views on this platform. #act #ssd #ciad #dip #m2mpharma

SSD: This is a Solid-State Dossier for our client which we often prepare after any processes (for an example micronisation, milling, spray drying, rotary evaporation, freeze drying). We analyse at t=0, then store the processed sample (API and/or formulation) in stability, withdraw a sub sample each week for 12 weeks. After 3 months, our clients get data which tell them the effect of processes on materials upon storage in various conditions. There are four key elements which our clients often appreciate: a) Arguably the only place which has so many calorimeters, 2xDVS, XRPD, TGA, DSC, iGC, PSD (Malvern, Sympatec both wet and dry), Pycnometer, BET-SSA, Morphology 4ID, Renishaw’s RA802, PLM, microCT, SEM* and all in-house. * collaboration b) 20 years of experience c) Real time data d) Agility If you are interested on this platform to reduce risk, money, time and facilitate your product development program then please reach out to us. We will be delighted to collaborate and help. #ssd #m2mpharma

What is ACT: This is a proprietary platform developed by us to answer amorphous content determination methods for inhaled APIs and products. This is embedded with 20 years of experience and some of the most sensitive techniques (SolCal, Perfusion Cal, microCal, DVS), one can think of. We will be exhibiting and running a workshop at RDD, Asia and then at DDL. So, if you have a question on this and want to discuss then please let us know. #amorphouscontenttesting #rddasia #ddl